Breast cancer is a type of cancer that develops in breast cells. While breast cancer potentially affects males as well, it affects women much more frequently. Breast cancer accounts for more than 1 in 10 newly diagnosed cancers in women each year, making it the most prevalent cancer.
Breast cancer grows gradually at all times. The majority of people discover they have this condition during routine screenings. This cancer has the potential to spread lymphatically and hematologically, which might result in distant metastases and a poor prognosis. This underlines the significance of breast cancer screening programs.
• Sometimes breast cells start to develop abnormally, which leads to breast cancer. These cells continue to multiply and divide more frequently than healthy cells do, producing a bulge or lump
• Cells may spread (metastasize) from the breast to the lymph nodes or other parts of the body
• Breast cancer generally develops from cells in the ducts that produce milk (invasive ductal carcinoma)
• Breast cancer can also develop in other cells or tissues inside the breast, including the glandular tissue known as the lobules (invasive lobular carcinoma)
• The risk of developing breast cancer may be increased by hormonal, lifestyle, and environmental characteristics
• Inherited breast cancer-
About 5 to 10 percent of breast cancers are generally caused by DNA alterations passed down through families.
Several inherited mutant genes can elevate the risk of developing breast cancer
Breast cancer gene 1 (BRCA1) and breast cancer gene 2 (BRCA2) are the two genes that raise the risk of breast cancer
A higher risk of breast cancer is linked to the following factors:
• Gender - Breast cancer is considerably more likely to affect women than men. Invasive breast cancer affects 1 in 8 women in the United States (12.4%) during their lifetime
• Obesity – Having increased adipose deposits raises estrogen levels, which increases the risk of developing breast cancer
• A personal history of breast conditions – breast biopsy revealed to have lobular carcinoma in-situ or atypical hyperplasia reduces the risk of breast cancer
• A personal history of breast cancer – more likely to get breast cancer in the right breast if you have already had breast cancer left breast and vice versa
• A family history of breast cancer - incidence of breast cancer is higher if family members (mother, sister, or daughter) have been diagnosed with breast cancer
• Inherited genes that increase cancer risk - The BRCA1 and BRCA2 gene mutations are the most commonly known variants. The risk of developing breast cancer and other malignancies may be significantly increased by these genes
• Radiation exposure - Breast cancer risk is elevated because of chest radiation treatments as a child or young adult
• Early Menarche - The cause of early menarche may be estrogens, which enhance breast cell proliferation and have been linked to a higher risk of breast cancer
• Postmenopausal hormone therapy - Breast cancer risk is higher for women who use estrogen and progesterone-containing hormone therapy drugs to manage menopausal symptoms.
1.
Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.
2.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
3.
Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap
4.
Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma
5.
Potential new therapy for childhood brain cancer could heal treatment-resistant tumors
1.
What is Hemorrhagic Cystitis and How to Manage its Symptoms
2.
How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?
3.
Blood Donation Sustainability Through Behavioral Science
4.
Emerging Therapies and Technologies Reshaping Oncology: Innovations and Impact in 2025
5.
Essential Developments in Oncology for Healthcare Excellence
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation